Skip to main content
BioAffinity secures $4M-plus in financing round

A round of Series A financing has pulled in over $4 million for San Antonio-based bioAffinity Technologies, maker of the CyPath early-stage lung cancer test. The money will be used to commercialize bioAffinity's lung cancer test and further develop tests and therapeutics for cancer, said company President and CEO Maria Zannes.

Full Story: